β-Cell Function in Subjects Spanning the Range from Normal Glucose Tolerance to Overt Diabetes: A New Analysis
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The nature of the progressive beta-cell failure occurring as normal glucose tolerant (NGT) individuals progress to type 2 diabetes (T2DM) is incompletely understood. We measured insulin sensitivity (by a euglycemic insulin clamp) and insulin secretion rate (by deconvolution of plasma C-peptide levels during an oral glucose tolerance test) in 188 subjects [19 lean NGT (body mass index [BMI] </= 25 kg/m(2)), 42 obese NGT, 22 BMI-matched impaired glucose tolerance [IGT], and 105 BMI-matched T2DM]. Main determinants of beta-cell function on the oral glucose tolerance test were derived from a mathematical model featuring the following: 1) glucose concentration-insulin secretion dose response (glucose sensitivity), 2) a secretion component proportional to the derivative of plasma glucose concentration (rate sensitivity); and 3) a potentiation factor. When NGT and T2DM were subgrouped by 2-h plasma glucose concentrations, insulin secretion rate revealed an inverted U-shaped pattern, rising through NGT up to IGT and falling off thereafter. In contrast, beta-cell glucose sensitivity dropped in a monophasic, curvilinear fashion throughout the range of 2-h plasma glucose. Within the NGT range (2-h glucose of 4.1-7.7 mmol/liter), beta-cell glucose sensitivity declined by 50-70% (P < 0.02). Insulin sensitivity decreased sharply in the transition from lean to obese NGT and then declined further in IGT and mild T2DM to level off in the higher three quartiles of diabetic hyperglycemia. In T2DM, defective beta-cell potentiation and rate sensitivity also emerged (P </= 0.05). In the whole data set, insulin sensitivity and the dynamic parameters of beta-cell function explained 89% of the variability of 2-h plasma glucose levels. The following conclusions were reached: 1) beta-cell glucose sensitivity falls already within the NGT range in association with rising 2-h plasma glucose concentrations, although absolute insulin secretion rates increase; and 2) throughout the glucose tolerance range, dynamic parameters of beta-cell function (glucose sensitivity, rate sensitivity, and potentiation) and insulin sensitivity are independent determinants of 2-h plasma glucose levels.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The slope of the relationship between glucose and insulin secretion (ie, β -CGS) is a major controller of postprandial glu cose levels (23, 24).”
From Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test (2024) · cites this paper as [24]
Citations
Cites
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Self-citationInsulin signalling and the regulation of glucose and lipid metabolism
Saltiel, A. R., & Kahn, C. R. (2001) · Nature · doi:10.1038/414799a · Cited by 5,326
Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940 · cited 2×
“5] -cell glucose sensitivity (pmol min 1 m 2 mM (1)) 147 [97] 92 [98] 55 [34] 14 [15]”
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
McGarry, J. D. (2002) · Diabetes · doi:10.2337/diabetes.51.1.7 · Cited by 1,435
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405
Martin, B. C., Warram, J. H., Krolewski, A. S., Soeldner, J. S., Kahn, C. R., Martin, B. C., & Bergman, R. N. (1992) · The Lancet · doi:10.1016/0140-6736(92)92814-v · Cited by 1,158
Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications
Unger, R. H. (1995) · Diabetes · doi:10.2337/diab.44.8.863 · Cited by 1,100
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 1×
“Fasting plasma insulin (pmol/liter) 20 [16] 48 [32] 74 [47] 94 [58] Insulin AUC (nmol/liter h) 22 [15] 45 [38] 65 [33] 24 [23] I/ G (pmol/mmol) 73 [84] 163 [172] 122 [140] 19 [33] Fasting ISR (pmol/min m (2)) 53 [34] 85 [53] 116 [39] 112 [71] Total IS (nmol m (2)) 30 [18] 43 [19] 47 [17] 24 [19] Insulin sensitivity (M…”
Cited by
Items 301–400 of 538
Eguchi, N., Toribio, A. J., Alexander, M., Xu, I., Whaley, D. L., Hernandez, L. F., Dafoe, D. C., & Ichii, H. (2022) · Biomedicines · doi:10.3390/biomedicines10020472 · Cited by 18
“As glycemia increases, insulin secretion rates from the β-cells become less responsive to changes in the glucose level, especially compared with non-diabetic subjects [10].”
BackgroundAssessment of β-cell function in human patients
Choi, C. S., Kim, M. Y., Han, K., & Lee, M. (2012) · Islets · doi:10.4161/isl.19270 · Cited by 22
Insulin management in overweight or obese type 2 diabetes patients: the role of insulin glargine
Davies, M. J., & Khunti, K. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00844.x · Cited by 19
“progressive dysfunction in β-cell function [ 16 ].”
BackgroundEndurance Training Improves GLP-1 Sensitivity and Glucose Tolerance in Overweight Women
Åkerström, T., Stolpe, M. N., Widmer, R., Dejgaard, T. F., Højberg, J. M., Møller, K., Hansen, J. S., Trinh, B., Holst, J. J., Thomsen, C., et al. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac111 · Cited by 15
“Among the characteristics of the dysfunctional beta cell in type 2 diabetes and prediabetes is an attenuated incretin effect [10-14].”
BackgroundMari, A., Stefański, A., van Raalte, D. H., Ma, X., LaBell, E. S., Fan, L., Lee, C. J., Thomas, M. K., Bunck, M. C. M., & Ferrannini, E. (2025) · Diabetes Care · doi:10.2337/dc25-0763 · Cited by 23
Self-citationJanssen, J. A. M. J. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189191 · Cited by 20
“For example, Ferrannini et al. found increased plasma insulin levels in subjects with normal or near normal glucose tolerance [13].”
Diabetes mellitus: Complications, emerging therapeutic targets, and evolving treatment approaches
Mohd, S., Kumar, L. L., Harish, V., Kumar, R., Chaudhary, A., & Sharma, V. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100652 · Cited by 28
Pedersen, L. R., Olsen, R. H., Jürs, A., Anholm, C., Fenger, M., Haugaard, S. B., & Prescott, E. (2015) · Metabolism · doi:10.1016/j.metabol.2015.07.007 · Cited by 19
“[40] Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo Ra.”
BackgroundAssessing Replication and Beta Cell Function in Adenovirally-transduced Isolated Rodent Islets
Fueger, P. T., Hernandez, A. M., Chen, Y., & Colvin, E. S. (2012) · Journal of Visualized Experiments · doi:10.3791/4080 · Cited by 15
Diabetes - Damages and Treatments
Rigobelo, E. C. (2011) · InTech eBooks · doi:10.5772/1823 · Cited by 17
Frias, P. F., & Frías, J. P. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0926-8 · Cited by 15
Elder, D. A., Hornung, L. N., Khoury, J. C., & D’Alessio, D. A. (2017) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2017.06.007 · Cited by 15
Cravalho, C. K. L., Meyers, A. G., Mabundo, L. S., Courville, A. B., Yang, S. B., Cai, H., Dai, Y., Walter, M. F., Walter, P. J., Sharma, S., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05236-y · Cited by 18
“surrogate markers of insulin sensitivity and insulin secretion were calculated using the whole-body insulin sensitivity index (WBISI) [24] and the insulinogenic index (IGI) [25], respectively.”
MethodInfluentialEarly use of insulin in type 2 diabetes
Eldor, R., Stern, E., Miličević, Z., & Raz, I. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.03.004 · Cited by 15
“Both these processes begin before the onset of hyperglycaemia [8], which develops only when increasing peripheral insulin demands fail to be met by the ailing beta cell.”
BackgroundBlüher, M., Malhotra, A., & Bader, G. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14969 · Cited by 15
Moon, J. H., Choe, H. J., & Lim, S. K. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14221 · Cited by 15
“By the time type 2 diabetes mellitus is clinically diagnosed, pancreatic b -cell functionality is typically halved 3 , a deduction corroborated by autopsy studies revealing a 40 – 60% reduction in b -cell mass in individuals with type 2 diabetes mellitus compared with those without diabetes 2,4,5 .”
BackgroundGastaldelli, A., Nauck, M. A., & Balena, R. (2013) · Metabolism · doi:10.1016/j.metabol.2013.05.001 · Cited by 15
“This is considered the best approach to evaluate ISR and beta cell function during postprandial state [37].”
BackgroundSelf-citationPediatric drug development programs for type 2 diabetes: A review
Christensen, M. L., Franklin, B. E., Momper, J. D., & Reed, M. D. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.497 · Cited by 14
Giuseppe, G. D., Ciccarelli, G., CEFALO, C. M. A., Cinti, F., Moffa, S., Impronta, F., Capece, U., Pontecorvi, A., Giaccari, A., & Mezza, T. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.21.03405-9 · Cited by 17
Brodovicz, K. G., Dekker, J. M., Rijkelijkhuizen, J. M., Rhodes, T., Mari, A., Alssema, M., Nijpels, G., Williams‐Herman, D., & Girman, C. J. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03315.x · Cited by 15
Self-citationBrain substrate metabolism and ß‐cell function in humans: A positron emission tomography study
Rebelos, E., Mari, A., Bucci, M., Honka, M., Hannukainen, J. C., Virtanen, K. A., Hirvonen, J., Nummenmaa, L., Heni, M., Iozzo, P., et al. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.136 · Cited by 14
“Total insulin output (nmol m−2) 40 [22] 48 [16] 44 [18] 44 [11] -”
Self-citationPathogenesis of Type 2 Diabetes Mellitus
DeFronzo, R. A. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_8 · Cited by 16
Self-citationThe Early Diabetes Intervention Program – is early actually late?
Bergman, M. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2563 · Cited by 14
“absolute insulin secretion rates increased [34].”
Corrêa, F. H., Nogueira, V. G., Bevilácqua, M. D. F., & Gomes, M. B. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000900013 · Cited by 14
Pathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch25 · Cited by 37
Self-citationHIF-2α Preserves Mitochondrial Activity and Glucose Sensing in Compensating β-Cells in Obesity
Moon, J.-S., Riopel, M., Seo, J. B., Herrero-Aguayo, V., Isaac, R., & Lee, Y. S. (2022) · Diabetes · doi:10.2337/db21-0736 · Cited by 13
Exploring the potential role of C‐peptide in type 2 diabetes management
Lin, Y., McCrimmon, R. J., & Pearson, E. R. (2025) · Diabetic Medicine · doi:10.1111/dme.15469 · Cited by 20
Prediabetes: Evaluation of β-Cell Function
Basu, A., Pedersen, M. G., & Cobelli, C. (2012) · Diabetes · doi:10.2337/db11-1677 · Cited by 18
“(5) used an OGTT model and reported that while the static response of insulin secretion was decreased in IGT, the dynamic response to a change in glucose was intact.”
MethodWang, H., Zhou, Y., Wang, Y., Cai, T., Hu, Y., Jing, T., Ding, B., Su, X., Li, H., & Ma, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.791439 · Cited by 13
Insulin Tactics in Type 2 Diabetes
Meah, F. A., & Juneja, R. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.08.021 · Cited by 15
A 3-year follow-up study of β-cell function in patients with early-onset type 2 diabetes
Zhou, S., Meng, X., Wang, S., Ren, R., Hou, W., Huang, K., & Shi, H. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3394 · Cited by 13
Vidmar, A. P., Durazo-Arvizú, R., Weigensberg, M. J., Alderete, T. L., & Goran, M. I. (2023) · Diabetes · doi:10.2337/db22-1034 · Cited by 13
Bala, C. G., Rusu, A., Ciobanu, D. M., Craciun, A. E., & Román, G. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s162086 · Cited by 12
Martínez‐Sánchez, F. D., Vargas-Abonce, V. P., Rocha-Haro, A., Flores-Cárdenas, R., Fernández-Barrio, M., Guerrero-Castillo, A. P., Meza-Arana, C. E., Gulías-Herrero, A., & Gómez-Sámano, M. Á. (2021) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2021.100013 · Cited by 17
Yamauchi, Y., Nakamura, A., Yokota, T., Takahashi, K., Kawata, S., Tsuchida, K., Omori, K., Nomoto, H., Kameda, H., Cho, K. Y., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-13888-6 · Cited by 14
“5 mmol/L), and N,N,N’,N’-tert-methyl-p-phenyldiamine (TMPD, 2 mmol/L), and (7) sodium azide (10 mmol/L).”
Balancing needs and means: the dilemma of the β‐cell in the modern world
Leibowitz, G., Kaiser, Ν., & Cerasi, E. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01101.x · Cited by 12
mTOR Inhibition: Reduced Insulin Secretion and Sensitivity in a Rat Model of Metabolic Syndrome
Rovira, J., Ramírez-Bajo, M. J., Bañón-Maneus, E., Moya‐Rull, D., Ventura‐Aguiar, P., Hierro-Garcia, N., Lazo-Rodríguez, M., Revuelta, I., Torres, A., Oppenheimer, F., et al. (2016) · Transplantation Direct · doi:10.1097/txd.0000000000000576 · Cited by 12
Two- vs one-hour glucose tolerance testing: Predicting prediabetes in adolescent girls with obesity
Kasturi, K., Onuzuruike, A. U., Kunnam, S., Shomaker, L. B., Yanovski, J. A., & Chung, S. T. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12803 · Cited by 13
Pathogenesis of Type 2 Diabetes Mellitus
Kalin, M. F., Goncalves, M., John‐Kalarickal, J., & Fonseca, V. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_13 · Cited by 15
Qureshi, F. M., Panzer, J. K., Põder, J., Malek, T. R., & Caicedo, A. (2023) · Diabetes · doi:10.2337/db22-0482 · Cited by 12
Armato, J., DeFronzo, R. A., Abdul‐Ghani, M. A., & Ruby, R. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae540 · Cited by 13
Self-citationStudy on the mechanism of plant metabolites to intervene oxidative stress in diabetic retinopathy
Gong, T., Wang, D., Wang, J., Huang, Q., Zhang, H., Liu, C., Liu, X., & Ye, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1517964 · Cited by 11
“It has inhibitory effects on a variety of diabetes targets, including α -glucosidase, α -amylase, and peroxisome proliferator-activated receptor γ (Ferrannini et al., 2005; Matsui et al., 2001).”
Bloomgarden, Z. T. (2011) · Diabetes Care · doi:10.2337/dc10-2235 · Cited by 11
“Cross-sectional data suggest that, as the fasting glucose increases from under 100 to 100–140 and again from 140 to 180 mg/dL, there is particularly great deterioration in b-cell function, with lesser deterioration as glucose levels increase further (1).”
LEVIN, P. A., Zhou, S., Durden, E., Farr, A. M., Gill, J., & Wei, W. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.11.011 · Cited by 11
Forbes, S., Lam, A. P., Koh, A., Imes, S., Dinyari, P., Malcolm, A. J., Shapiro, A. M. J., & Senior, P. A. (2018) · Clinical Transplantation · doi:10.1111/ctr.13301 · Cited by 13
Low Serum IGF-I/GH Ratio Is Associated with Abnormal Glucose Tolerance in Acromegaly
Fukuoka, H., Takahashi, Y., Iida, K., Kudo, T., Nishizawa, H., Imanaka, M., Takeno, R., Iguchi, G., Takahashi, K., Okimura, Y., et al. (2008) · Hormone Research in Paediatrics · doi:10.1159/000112590 · Cited by 11
“Insulin-secreting ability was estimated by IGI calculating as [insulin at time 30 min – insulin at time 0 min (μU/ml)]/[glucose at time 30 min – glucose at time 0 min (mg/dl)] in 75 g OGTT [”
MethodInsulin resistance and cardiovascular outcomes in the ORIGIN trial
Gerstein, H. C., Ferrannini, E., Riddle, M. C., Yusuf, S., & ORIGIN Trial Investigators (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13112 · Cited by 13
Self-citationPathogenesis of Type 2 Diabetes Mellitus
DeFronzo, R. A. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_8-1 · Cited by 13
Self-citationMyocardial glucose uptake in patients with the m.3243A > G mutation in mitochondrial DNA
Lindroos, M. M., Pärkkä, J. P., Taittonen, M. T., Iozzo, P., Kärppä, M., Hassinen, I. E., Knuuti, J. M., Nuutila, P., & Majamaa, K. (2015) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-015-9865-1 · Cited by 11
(2011) · Wiley eBooks · doi:10.1002/9781119950424.ch5 · Cited by 12
The pathophysiology of glucose intolerance in newly diagnosed, untreated T2DM
Dunseath, G. J., Luzio, S. D., Peter, R., & Owens, D. R. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01785-9 · Cited by 15
Mathew, G. M., Nahmod, N. G., Master, L., Reichenberger, D., Rosinger, A. Y., & Chang, A. (2023) · Sleep Health · doi:10.1016/j.sleh.2023.10.006 · Cited by 13
Shen, Y., Si, Y., Lu, J., Ma, X., Zhang, L., Mo, Y., Lu, W., Zhu, W., Bao, Y., Hu, G., et al. (2020) · Journal of Diabetes Research · doi:10.1155/2020/4243053 · Cited by 11
“The reduced acute insulin response is the major reason for postprandial hyperglycemia [17].”
BackgroundVivek, S., Carnethon, M. R., Prizment, A. E., Carson, A. P., Bancks, M. P., Jacobs, D. R., & Thyagarajan, B. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109004 · Cited by 10
Continuous Subcutaneous Insulin Infusions: Closing the Loop
Díaz-Balzac, C. A., Pillinger, D., & Wittlin, S. D. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac746 · Cited by 11
Ekanayake, P. S., & Edelman, S. V. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15059 · Cited by 10
“Although there are many noninsulin glucose-lowering medication options, the natural history of T2D involves the loss of beta-cell function over time, necessitating the addition of basal and often prandial insulin.(1,2) This is demonstrated in several key trials,(3,4) including the landmark 4-T study, showing that 80%…”
BackgroundPhysiologic Insulin Resensitization as a Treatment Modality for Insulin Resistance Pathophysiology
Greenway, F. L., Loveridge, B., Grimes, R. M., Tucker, T. R., Alexander, M., Hepford, S. A., Fontenot, J., Nobles‐James, C., Wilson, C., Starr, A. M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031884 · Cited by 11
Lotz, T., Göltenbott, U., Chase, J. G., Docherty, P. D., & Hann, C. E. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300435 · Cited by 12
“This delay can be attributed to a delay in pancreatic response to insulin input in the case of D4 [24] and an increased total demand and production rate during this stage, in D5 [1].”
Backgroundden Biggelaar, L. J. C. J., Eussen, S. J. P. M., Sep, S. J. S., Mari, A., Ferrannini, E., van Greevenbroek, M. M. J., Kallen, C., Schalkwijk, C. G., Arts, I. C. W., Stehouwer, C. D. A., et al. (2018) · European Journal of Nutrition · doi:10.1007/s00394-018-1644-y · Cited by 13
“Moreover, significant changes in BCF not resulting in the development of T2DM are taken into account, which is important as the impairment of BCF starts already in the normal glucose metabolism range [17].”
BackgroundSelf-citationCell therapy for type 2 diabetes: is it desirable and can we get it?
Halban, P. A. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00957.x · Cited by 14
Alvarez-Canales, M. F. D. L. L., Salazar-López, S. S., Farfán-Vázquez, D., Martínez-López, Y. E., González-Mena, J. N., Jiménez-Ceja, L. M., Vargas‐Ortiz, K., Evia-Viscarra, M. L., de Oca-Loyola, M. L. M., Folli, F. B., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-88108-8 · Cited by 8
Pancreatic β-cell dysfunction in normoglycemic patients and risk factors
Vilchis-Flores, L. H., Barajas-Medina, G. A., Villa-Martínez, A., López, S. S. S., Luna-Patiño, G. A., Quiroz-Hernández, M. E., Guzmán-Vanegas, M. A., Rodríguez-Cortés, R., Angulo-Romero, F., Reyes‐Escogido, M. D. L., et al. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01411-9 · Cited by 190
Genome-Wide Association Analysis of Pancreatic Beta-Cell Glucose Sensitivity
Deshmukh, H., Madsen, A. L., Viñuela, A., Have, C. T., Grarup, N., Tura, A., Mahajan, A., Heggie, A. J., Koivula, R. W., Masi, F. D., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa653 · Cited by 10
Self-citationIs β-cell failure in type 2 diabetes mellitus reversible?
Kabadi, U. M., Kabadi, M., & Jain, R. (2008) · International Journal of Diabetes in Developing Countries · doi:10.4103/0973-3930.41978 · Cited by 9
The pancreatic β-cell transcriptome and integrated-omics
Blodgett, D. M., Cura, A. J., & Harlan, D. M. (2014) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000051 · Cited by 11
Aizawa, T., Yamada, M., Katakura, M., Funase, Y., Yamashita, K., & Yamauchi, K. (2011) · Endocrine Journal · doi:10.1507/endocrj.ej11-0162 · Cited by 9
“Ethnic diversity may play a role with Japanese subjects being leaner and more insulin sensitive [5, 15, 19, 38, 39 and current data] than subjects in Caucasian [6-8, 10-14, 17, 18] at a comparable level of glucose regulation.”
BackgroundAbnormalities of Insulin Secretion and β‐Cell Defects in Type 2 Diabetes
Alsahli, M., & Gerich, J. E. (2010) · Wiley eBooks · doi:10.1002/9781444324808.ch10 · Cited by 18
Continuous glucose monitoring as a tool in early-stage type 1 diabetes
Carr, A. L. J., Sutton, H., Agesen, R. M., Bonifacio, E., Bosi, E., Gillard, P., Swaby, R., Vercauteren, J., & Besser, R. E. J. (2026) · Diabetologia · doi:10.1007/s00125-026-06707-4 · Cited by 10
“More complex modelling approaches such as the oral minimal model [65, 66] allow estimation of insulin sensitivity and beta cell responsivity from OGTT data, possibly offering greater granularity in dissecting metabolic heterogeneity in the early stages of disease [38, 39, 67].”
Lin, Z., Zhou, J., Li, X., Song, L., Hou, X., Tang, J., Wang, C., & Jia, W. (2014) · Endocrine · doi:10.1007/s12020-014-0244-8 · Cited by 8
Deischinger, C., Harreiter, J., Leitner, K., Bancher‐Todesca, D., Baumgartner-Parzer, S. M., & Kautzky‐Willer, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072277 · Cited by 8
Mari, A., Rosenstock, J., Ma, X., Li, Y. G., & Jackson, J. A. (2015) · Endocrine Practice · doi:10.4158/ep15898.or · Cited by 9
Self-citationMehta, R. J., Gastaldelli, A., Balas, B. I., Ricotti, A., DeFronzo, R. A., & Tripathy, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174230 · Cited by 8
“Postprandial hyperglycemia results from insulin resistance in muscle [7], impaired suppression of hepatic glucose production [3,8], and decreased insulin secretion [9,10].”
BackgroundSelf-citationA glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment
Subramanian, V., Bagger, J. I., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.911616 · Cited by 10
Livadas, S., Dracopoulou, M., Lazaropoulou, C., Papassotiriou, I., Sertedaki, A., Angelopoulos, G. N., Chrousos, G. P., & Dacou‐Voutetakis, C. (2009) · Hormone Research in Paediatrics · doi:10.1159/000249161 · Cited by 9
“and (e) the Matsuda index using the formula: 10,000/√ (G × I) × (M G × M I ), where G and I denote fasting glucose and insulin values, whereas M G and M I denote mean glucose and insulin values during the oral glucose tolerance test, respectively [”
MethodType 2 diabetes mellitus: A disease of the governance of the glucose-insulin system
Trombetta, M., Boselli, L., Cretti, A., Cali, A. M. G., Vettore, M., Caruso, B., Dorizzi, R. M., Avogaro, A., Muggeo, M., Bonora, E., et al. (2011) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2011.05.006 · Cited by 10
“These data add a novel facet to the concept that beta cell failure perhaps is the key component of type 2 diabetes pathogenesis [2,4,5,7], in that this failure involves not only beta cell secretory function, but also its role in diabetic glucose homeostasis.”
BackgroundDmitriev, L. F., & Дугин, С. Ф. (2007) · Archives of Physiology and Biochemistry · doi:10.1080/13813450701384783 · Cited by 8
“It includes a variety of processes and reactions, among which sensitivity of these cells to glucose and insulin output are of primary importance (Ferrannini et al., 2005).”
BackgroundHansen, A. M. B., Wium, C., Lee-Ødegård, S., Tierney, A. C., McCarthy, D., Roche, H. M., Drevon, C. A., Birkeland, K. I., & Gulseth, H. L. (2020) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2020.1730433 · Cited by 10
“due to peripheral and hepatic insulin resistance [3].”
BackgroundIndividuation of different metabolic phenotypes in normal glucose tolerance test
Schianca, G. P. C., Colli, E., Onolfo, S., Pedrazzoli, R., Fra, G. P., & Bartoli, E. (2009) · Acta Diabetologica · doi:10.1007/s00592-009-0165-9 · Cited by 9
“In the last years, impairments in insulin sensitivity and secretion, like those recognized in IFG, IGT and type 2 diabetes [5, 13, 14], were also reported in subjects in the upper range of normal FPG or 2hPG values [15, 16].”
BackgroundÉvaluation de l’insulinosécretion et de l’insulinosensibilité
Scheen, A. J. (2007) · Therapies · doi:10.2515/therapie:2007053 · Cited by 8
Berstein, L. M., Цырлина, Е. В., Vasilyev, D. A., Евгеньевна, П. Т., & KOVALENKO, R. G. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1356.018 · Cited by 8
Docherty, P. D. (2011) · UC Research Repository (University of Canterbury) · doi:10.26021/2487 · Cited by 12
Pienimäki, T. (2014) · Cited by 10
Phosphodiesterase 5 Inhibitor Suppresses Prostate Weight Increase in Type 2 Diabetic Rats
Kobayashi, H., Zha, X., Nagase, K., Inamura, S., Taga, M., Aoki, Y., Ito, H., & Yokoyama, O. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120504 · Cited by 6
Nutrition‐/diet‐induced changes in gene expression in pancreatic β‐cells
Chadt, A., Yeo, G. S. H., & Al‐Hasani, H. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01640.x · Cited by 7
Patel, Y. R., Kirkman, M. S., Considine, R. V., Hannon, T. S., & Mather, K. J. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2056 · Cited by 7
Regulation of Intermediatory Metabolism During Fasting and Feeding
DeFronzo, R. A., & Ferrannini, E. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00036-8 · Cited by 7
Self-citationRole of Endocrine-Genotoxic Switchings in Cancer and Other Human Diseases:
Berstein, L. M. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-78818-0_3 · Cited by 7
Pathogenesis of Type 2 Diabetes Mellitus
Kalin, M. F., Goncalves, M., & Fonseca, V. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-20797-1_13-1 · Cited by 10
Staup, M. A., Aoyagi, G., Bayless, T., Wang, Y., & Chng, K. (2016) · Journal of Visualized Experiments · doi:10.3791/52895 · Cited by 7
Pathogenesis of Type 2 Diabetes Mellitus
Kalin, M. F., Goncalves, M., John‐Kalarickal, J., & Fonseca, V. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-20797-1_13-2 · Cited by 11
Therapy targeting β-cell survival and function in type 2 diabetes mellitus
Pørksen, N. K. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.06.014 · Cited by 8
“Similarly, insulin secretion following OGTT [22] and mixed meals [23] is also impaired.”
BackgroundStriving for early effective glycaemic and weight management in type 2 diabetes: A narrative review
CHENG, A. Y. Y., Heine, R. J., Prato, S. D., Green, J. B., Thieu, V. T., & Zeytinoglu, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16206 · Cited by 7
“24 As β -cell function is no longer able to sufficiently compensate for persistent insulin resistance, plasma glucose rises and the deleterious effects of hyperglycaemia begin to manifest.”
Ho, J. P. Y., Lau, E. S. H., Chun Kwan, O., Fan, B., Ko, G. T.-C., Kong, A. P.-S., Ching-Wan, R., Chow, E., Chan, J. C. N., & Luk, A. O. Y. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111718 · Cited by 6
Sun, X., Du, T., Huo, R., & Xu, L. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0515-5 · Cited by 4
Zhou, H., Yang, C., Dong, C., Guo, Z., Hu, X., Xu, Y., & Zhou, Z. (2014) · PubMed Central · Cited by 6
Ma, C., Liu, Y., He, S., Zeng, J., Li, P., Ma, C., Ping, F., Zhang, H., Xu, L., Li, W., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-6119 · Cited by 188
“Moreover, mounting evidence indicates a degree of β-cell dysfunction in individuals with prediabetes (including IFG and IGT), as well as in some individuals with NGT (2-4).”
BackgroundGenetic variation of ERN1 and susceptibility to type 2 diabetes
Klyosova, E. Y. (2022) · RESEARCH RESULTS IN BIOMEDICINE · doi:10.18413/2658-6533-2022-8-3-0-1 · Cited by 6
Getting to goal in newly diagnosed type 2 diabetes using combination drug “subtraction therapy”
Jennings, A. S., Lovett, A. J., George, T. M., & Jennings, J. S. (2015) · Metabolism · doi:10.1016/j.metabol.2015.04.008 · Cited by 7
“The natural history of diabetes is progressive loss of beta cell function, andwhen left untreated long enough, every patient loses the ability to secrete insulin in response to a glycemic challenge [22–24].”
BackgroundInsulin resistance and metabolic syndrome criteria in lean, normoglycemic college-age subjects
Townsend, D. K., McGregor, K., Wu, E. E., Cialkowski, K., Haub, M. D., & Barstow, T. J. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.03.025 · Cited by 7
Insulin Pulse Characteristics and Insulin Action in Non-diabetic Humans
LAURENTI, M. C., Man, C. D., Varghese, R. T., Andrews, J. C., Jones, J. G., Barosa, C., Rizza, R. A., Matveyenko, A. V., Nicolao, G. D., Bailey, K. R., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab100 · Cited by 6
Metadata
- Authors
- Ferrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A.
- Affiliations
- University of Pisa (IT)
- The University of Texas at San Antonio Health Science Center (US)
- National Research Council (IT)
- Corresponding author
- Ferrannini, Ele
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-01
- Volume
- 90
- Issue
- 1
- Pages
- 493-500
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1981581852
- Semantic Scholar
- 1e59c003bc095926431f049735ca1064ebb24a32
- Cited by
- 540
- References
- 45
- Citations by year
- 2026: 10 · 2025: 21 · 2024: 20 · 2023: 20 · 2022: 27 · 2021: 19 · 2020: 21 · 2019: 22 · 2018: 25 · 2017: 26 · 2016: 21 · 2015: 33 · 2014: 33 · 2013: 26 · 2012: 32
- FWCI
- 29.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 24092)
- National Center for Research Resources (M01RR01346, M01RR001346)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- beta-cell function, type 2 diabetes, impaired glucose tolerance, insulin sensitivity, insulin secretion rate, beta-cell glucose sensitivity, rate dependence, C-peptide, hyperinsulinemic-euglycemic clamp, oral glucose tolerance test, obesity, 2-hour plasma glucose
- MeSH terms
- Insulin Secretion, Adult, Blood Glucose, Cross-Sectional Studies, Diabetes Mellitus, Fatty Acids, Nonesterified, Female, Glucose Tolerance Test, Humans, Insulin, Insulin Resistance, Islets of Langerhans, Male, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.